Search company, investor...

EDP Biotech

edpbiotech.com

Founded Year

2005

Stage

Unattributed - V | Alive

Total Raised

$3.83M

About EDP Biotech

EDP Biotech Corporation is a privately held medical device company focused on the development and commercialization of blood-based immunodiagnostic assays.

Headquarters Location

6701 Baum Drive Suite 110

Knoxville, Tennessee, 37919,

United States

865-299-6250

EDP Biotech's Product Videos

Compete with EDP Biotech?

Ensure that your company and products are accurately represented on our platform.

EDP Biotech's Products & Differentiators

    ColoPlex

    RUO blood test for the early detection of colorectal cancer and pre-cancerous polyps

Expert Collections containing EDP Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EDP Biotech is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

EDP Biotech Patents

EDP Biotech has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Gastrointestinal cancer
  • Infectious causes of cancer
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/29/2014

9/5/2017

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Proteins

Grant

Application Date

4/29/2014

Grant Date

9/5/2017

Title

Related Topics

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Proteins

Status

Grant

Latest EDP Biotech News

Colorectal Cancer Market Research | Edition 2022 | Recent Developments and SWOT Analysis 2028

Jan 19, 2023

| Edition 2022 | Recent Developments and SWOT Analysis 2028 News Provided By Share This Article Douglas Insights Some key players in this market Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG. ISLE OF MAN, ISLE OF MAN, January 18, 2023 / EINPresswire.com / -- Colorectal Cancer Market Value and CAGR The global market for colorectal cancer is expected to grow from USD 5 billion in 2018 to over USD 10.2 billion by 2023, at a CAGR of 6.9%. In millions of people around the world, colorectal cancer is a serious health condition caused by the mutation of the gene that codes for the bowel cancer-causing molecule. If it is detected early enough, colorectal cancer can be treated successfully. Colorectal Cancer Market Growth Drivers and Risks Increasing awareness of CRC and escalating incidence rates are driving this market, mainly due to lifestyle changes like obesity and poor diet, as well as aging. Moreover, different types of treatments are available for CRC, which will augment its growth. As awareness of the risks associated with colorectal cancer and its symptoms increases, incidence rates, screening rates, and treatment rates increase, the market increases. Colorectal Cancer Market Key players Some key players in this market Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited. Check out the detailed TOC, Tables, and Figures with Charts for exclusive data, information, vital statistics, trends, and competitive landscape details. https://douglasinsights.com/colorectal-cancer-market Colorectal Cancer Market Segmentations Reasons Why You Should Buy This Report • The Colorectal Cancer Market report is a compilation of data from different sources and has been put together in a way that makes it easy for the reader to understand. • It covers a wide range of topics, including Colorectal Cancer Market current trends, market size, and forecasted growth. • The Colorectal Cancer Market report provides valuable insights that can help you make informed decisions about your business. The data is accurate and up-to-date, so you can trust the information presented. • This Colorectal Cancer Market report is an excellent resource for business owners who are looking to gain an understanding of the market landscape and potential opportunities. • It will help you identify growth sectors and predict future trends of Colorectal Cancer Market Table of content Follow Douglas Insights for More Industry Updates- @ LinkedIn & Twitter About Douglas Insights- Douglas Insights UK limited is the first company to provide comparison of market research reports by Table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions. With our advanced algorithm, filters, and comparison engine, you can compare your preferred reports simultaneously, based on publisher rating, published date, price, and list of tables. Our data portal enables you to find and review the reports from several publishers. You can evaluate numerous reports on the same screen and select the sample for your best match. Office- Isle of Man IM4 5HA, Isle of Man Email- isabella@douglasinsights.com

EDP Biotech Frequently Asked Questions (FAQ)

  • When was EDP Biotech founded?

    EDP Biotech was founded in 2005.

  • Where is EDP Biotech's headquarters?

    EDP Biotech's headquarters is located at 6701 Baum Drive, Knoxville.

  • What is EDP Biotech's latest funding round?

    EDP Biotech's latest funding round is Unattributed - V.

  • How much did EDP Biotech raise?

    EDP Biotech raised a total of $3.83M.

  • Who are the investors of EDP Biotech?

    Investors of EDP Biotech include Angel Capital Group, High Country Impact Fund, Sheltowee Medical Device Fund and CO.LAB.

  • Who are EDP Biotech's competitors?

    Competitors of EDP Biotech include Geneoscopy and 4 more.

  • What products does EDP Biotech offer?

    EDP Biotech's products include ColoPlex and 2 more.

Compare EDP Biotech to Competitors

D
Diagnostic Technologies

Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry. The company aims to become a major player in managing high risk pregnancies by commercialising a technology platform of versatile biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies.

Blueberry Diagnostics Logo
Blueberry Diagnostics

Blueberry Diagnostics is a biotechnology company. It offers AI testing solutions to healthcare professionals to detect cancer in its early stages. The company was founded in 2019 and is based in Wilmington, Delaware.

Cofactor Genomics Logo
Cofactor Genomics

Cofactor Genomics bridges the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Cofactor provides Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers for new diagnostics to improve patient outcomes.

X-Zell Logo
X-Zell

X-Zell is a simple blood test used to detect cancer early on by removing healthy cells from the blood sample and then depositing the cancer cells onto standard slides followed by an evaluation performed by a pathologist.

SimBioSys Logo
SimBioSys

SimBioSys is developing technology for exploring the economy of tumor microenvironments. Integrating the gamut of health data available for a patient, the capabilities within the TumorScope not only provide predictions for treatment outcomes, but provide the mechanism and reason why a treatment will succeed or fail. As a first target, SimBioSys is calibrating the TumorScope for the war on breast cancer.

A
Auspex

Auspex provides artificial intelligence-based advanced cancer diagnostics services intended to improve the quality of cancer care. The company's machine learning algorithm analyzes the genomic information of patients' tumor sample and accurately assess the risk of recurrence and drug efficacy, enabling the oncologists and patients to make the optimal data-driven decisions and personalize the treatment plan.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.